Paragon Therapeutics Decreases Stake in Damora Therapeutics (GLTO) to 3.39%

On April 23, 2026, Paragon Therapeutics, Inc. filed a Schedule 13G/A with the SEC, reporting a decrease in its ownership stake in Damora Therapeutics, Inc. (formerly Galecto, Inc., ticker: GLTO). As of the event date on February 9, 2026, Paragon Therapeutics holds 2,045,473 shares of Common Stock, representing a 3.39% ownership interest in the company. This filing marks an amendment to a previous statement, indicating that the filer's ownership has dropped below the 5% reporting threshold typically required for active Schedule 13G filings. The calculation of this percentage is based on 60,303,212 shares of Common Stock outstanding as reported in the issuer's Annual Report for the fiscal year ended December 31, 2025. Paragon Therapeutics, based in Waltham, MA, reported sole voting and dispositive power over all 2,045,473 shares. The filing certifies that the securities were not acquired for the purpose of changing or influencing the control of the issuer.